Abstract 192P
Background
Lung cancer is a disease that ranks among the first in incidence and mortality in Mexico and worldwide. Neuroendocrine tumors (NETs) have been studied for their neurological and endocrine characteristics; NETs are characterized by having active autocrine/paracrine communication with the microenvironment. Serotonin is precursor of melatonin, an indolamine that can exert immunomodulatory effects and is considered one of the molecules of the neuro-immuno-endocrine axis. The transmembrane protein death ligand 1 (PD-L1) is overexpressed in some types of cancer cells, giving them the ability to camouflage themselves against the immune system. The activation PD-1/PD-L1 are responsible for the proliferation, activation, and cytotoxic secretion of T cells in cancer to generate the antitumor immune response.
Methods
In this work neuroendocrine A549 cells were obtained by two different transdifferentiation methodologies for 72 hours with cAMP inducers in DMEM with 2% fetal bovine serum (NED2%) and without fetal bovine serum (NEDsSFB). This differentiation was corroborated through the evaluation of morphology by light microscopy and the expression of specific markers Chromogranin (CgA) and Synaptophysin (Syn) by rt-PCR. The expression of PD-L1 was assessed in A549 cells, NED2% and NEDsSFB groups by rt-PCR and flow cytometry. A co-culture was performed with the neuroendocrine models with T lymphocytes to observe the cytotoxic effect for 24 hours.
Results
The results showed a new neuroendocrine model, suggest an inhibitory effect in proliferation of melatonin and serotonin from concentrations of 2.5 mM and 0.5 μM respectively in both neuroendocrine models at 24 and 48 hours. It is confirmed for the first time the presence of PD-L1 in the neuroendocrine phenotypes cells of A549 (NED2% and NEDsSFB) and thus a mechanism for evasion of the immune system can be proposed.
Conclusions
We conclude with the development of a new neuroendocrine model as well as the possible mechanism of the decrease in the cytotoxic effect of T lymphocytes in neuroendocrine models.
Legal entity responsible for the study
Universidad Autónoma de Querétaro.
Funding
Universidad Autónoma de Querétaro Conahcyt.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract